Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

ey.com/cgi-bin/fulltext/123567330/PDFSTART.

About tapentadol

Tapentadol is a centrally acting oral analgesic that binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. The tapentadol molecule is classified as Schedule II of the Controlled Substances Act.

NUCYNTA® (tapentadol immediate release) was approved by the FDA on November 20, 2008, and is available by prescription only for the relief of moderate to severe acute pain in patients 18 years of age or older. On December 1, 2009, J&JPRD submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients 18 years of age or older. The tapentadol ER tablet formulation is designed to provide a high degree of mechanical resistance, such as to crushing or chewing. The NDA filing is part of the ongoing commitment of J&JPRD and PriCara® to bring new and innovative products to patients and physicians for the treatment and management of pain.

IMPORTANT SAFETY INFORMATION FOR NUCYNTA® (tapentadol)

Like other drugs with mu-opioid agonist activity, NUCYNTA® is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma or hypercapnia in unmonitored settings or in the absence of resuscitative equipment. NUCYNTA® is contraindicated in patients who have or are suspected to have paralytic ileus. NUCYNTA® is also contraindicated in patients currently using or within 14 days
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... Inc. (NYSE: RMD ) today announced results for ... was $423.0 million, a 10 percent increase compared to the ... a constant currency basis). Net income was $91.2 million, an ... 31, 2013. Diluted earnings per share for the quarter were ...
(Date:1/22/2015)... Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today announced ... financial results on Tuesday, Jan. 27, 2015, after the close of ... conference call with the investment community at 2 p.m. PT. Participating ... , chairman and chief executive officer, and other members of Amgen,s ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... As the economy recovery continues to lag, employers are ... health care costs. Running counter to these goals, independent ... employers, ability to save money by offering lower cost ... Management Association (PCMA) said today. "As the ...
... Stryker Joint Preservation, a business unit of Stryker,s ... Society for Sports Medicine meeting that it has entered ... Stryker,s RegenKit-THT, a one-step system designed for the safe ... a small sample of blood at the patient,s point ...
Cached Medicine Technology:As Economic Recovery Sputters, Independent Drugstores Shouldn't Shoulder Employers With Higher Costs 2Stryker Announces Exclusive Collaboration With RegenLab 2
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Janakpur zonal hospital found themselves in peril after doctors ... resignation.// The resignation en masse was submitted on Sunday, ... to doctors – said senior physician Dr Gaurang Mishra. ... and Dr. Raj Kumar Mahoto were beaten up by ...
... a grim fact. Diseases like diabetes, heart conditions,// kidney ... is that fifty per cent of these diseases are ... lifestyle diseases can be avoided by quitting wrong habits ... exercising enough. , “Unless Queenslanders make informed ...
... public. A decade after genetically altered crops were first ... disinclined towards them. ,According to a survey sponsored ... last five years have seen little change in the ... director of the survey’s sponsor, Michael Fernandez, “Americans are ...
... prevalence of infectious diseases like tuberculosis and meningitis in ... on the importance of specialization in such diseases during ... the US, where infectious diseases specialty has been present ... focused upon adequately. The result is while there are ...
... rehabilitation clinic no. 17,faced one of the most deadliest fires that ... //. 45 women were killed because of burns, and smoke asphyxiation. ... of 35.Some were HIV patients and few suffered from severe psychological ... few months ago that the building was not safe ,and ...
... suffer through a range of problems, from poor grades ... than half of these children also have serious problems ... learning to develop the social skills they need to ... with ADHD often are peer-rejected, and their difficulties multiply ...
Cached Medicine News:Health News:Gene-Altered Foods ? Still Not Sure 2Health News:India’s Need for Specialization in Infectious Diseases Urge 2Health News:Friendship Clinic: Psychologist Helps Children With ADHD Make Friends 2Health News:Friendship Clinic: Psychologist Helps Children With ADHD Make Friends 3
... Introducing Quieter Compressed Air., ,Allied Healthcares Timeter® ... quieter than other air compressors that you may ... too. The PCS 414 features a durable, mar-resistant ... And, the unit weighs only 26.5 pounds. The ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
Portable Compressor Nebulizer...
The AeroMax nebulizer compressor features convenient storage space for medications and accessories. Aluminum compressor components ensure a long, trouble-free life and consistent performance. Rx ONLY...
Medicine Products: